Assembly Biosciences, INC 8-K filings
NASDAQ
8-K: Assembly Biosciences Stockholders Approve Reverse Stock Split and Share Issuance to Gilead Sciences
Assembly Biosciences' stockholders approved a reverse stock split and the issuance of shares to Gilead Sciences at a special meeting on January 31, 2024.
NASDAQ
Assembly Biosciences has terminated its license agreement with Indiana University Innovation and Commercialization Office, ending its obligations related to its first-generation hepatitis B capsid assembly modulator.